Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 192 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 192
- Q2 2026, −14 vs. previous quarter
- 13F value
- $646.8M
- Reported value at the end of Q2 2026
- Superinvestors holding
- 1
- At the end of Q2 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $403.1M
- +21.3% year over year
- Net income, FY2025
- -$22.7M
- No comparable prior period
- Free cash flow, FY2025
- -$13.1M
- No comparable prior period
- Revenue, Q1 FY2026
- $80.1M
- +23.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $22.7M (5.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Jun 30, 2026.
- Short interest
- 17.4M
- Shares sold short
- Change
- −3.32M
- −16.0% vs. previous
- Days to cover
- 1.74
- At average daily volume
Superinvestors holding ESPR, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Esperion Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
<0.1%
Esperion Therapeutics, Inc.'s share of the portfolio
- Shares
- 757,358
- Value
- $2.39M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Esperion Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Looker BenjaminChief Legal Officer | SSale | −11.8K | $3.16 | −$37.4K | −1.7%667.5K after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −53.6K | $3.16 | −$169.3K | −2.5%2.12M after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −10.8K | $3.16 | −$34.0K | −1.5%702.8K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Looker BenjaminChief Legal Officer | SSale | −5.71K | $2.70 | −$15.4K | −0.8%679.3K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −25.6K | $2.72 | −$69.6K | −1.2%2.17M after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −6.42K | $2.71 | −$17.4K | −0.9%713.6K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Looker BenjaminGeneral Counsel | SSale | −1.69K | $2.88 | −$4.86K | −0.4%384.2K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −48.2K | $3.67 | −$177.1K | −3.2%1.47M after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −7.34K | $3.67 | −$26.9K | −1.5%467.5K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Looker BenjaminGeneral Counsel | SSale | −6.52K | $3.67 | −$23.9K | −1.7%385.9K after |
Top 10 13F holders, Q2 2026
See all 192 holdersThe largest institutional positions in Esperion Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Glazer Capital, LLC | 22,416,339 | $70.8M | 1.75% | +22,416,339 | New |
| BlackRock, Inc. | 22,128,021 | $69.9M | 0.00% | +4,275,594+23.9% | Added |
| Vanguard Capital Management LLC | 11,427,437 | $36.1M | 0.00% | +993,677+9.5% | Added |
| Trium Capital LLP | 11,158,150 | $35.3M | 22.22% | +11,158,150 | New |
| Goldman Sachs Group Inc | 10,380,646 | $32.8M | 0.00% | +7,970,192+330.7% | Added |
| State Street Corp | 7,276,249 | $23.0M | 0.00% | +220,455+3.1% | Added |
| Two Sigma Investments, LP | 7,126,739 | $22.5M | 0.02% | −2,332,040−24.7% | Reduced |
| Geode Capital Management, LLC | 6,629,966 | $21.0M | 0.00% | +674,227+11.3% | Added |
| CNH Partners LLC | 6,046,463 | $19.1M | 0.27% | +6,046,463 | New |
| Oddo BHF Asset Management SAS | 5,000,000 | $15.8M | 0.73% | +5,000,000 | New |
Holders of 5% or more of ESPR
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Esperion Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Glazer Capital, LLC | 13G | 8.15%21.0M shares | New | Jun 8, 20261 filing | Jun 8, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.08%13.1M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |